Background
==========

Hodgkin lymphoma (HL) is one of the most common lymphomas in the Western world: it accounts for 30% of all lymphomas and 15% of all malignancies in young adults \[[@b1-medscimonit-22-2340],[@b2-medscimonit-22-2340]\]. On the basis of difference in the morphology, phenotype of the lymphoma cells, and the composition of inflammatory infiltrate, HL is divided into classical HL (cHL), subtyped into nodular sclerosis (NS), mixed cellularity (MC), lymphocyte rich (LR), and lymphocyte depleted (LD); and nodular lymphocyte predominant HL (NLPHL), which accounts for only 5% of HL \[[@b3-medscimonit-22-2340],[@b4-medscimonit-22-2340]\]. In industrialized countries HL presents with a bimodal age distribution, with a rise in incidence in young adults (20--34 years) and in elderly people (55--75 years). In developing countries, the first peak occurs earlier, in children and teenagers. Also, an inverse correlation between incidence of HL and socioeconomic status was observed \[[@b5-medscimonit-22-2340]--[@b7-medscimonit-22-2340]\]. A prerequisite for the diagnosis of HL is malignant mononuclear Hodgkin cells and multinuclear Reed-Sternberg cells (HRS), which represent only 1--10% of the total tumor mass and reside in abundant inflammatory infiltrate. The origin of HRS cell has long been an enigma due to the global loss of B cell phenotype and aberrant expression of markers characteristic of T cells or dendritic cells \[[@b3-medscimonit-22-2340],[@b4-medscimonit-22-2340]\]. In 1994 Kuppers discovered that HRS are derived from pre-apoptotic germinal center B cells that have acquired disadvantageous "crippling" mutations, and in normal circumstances would have undergone apoptosis \[[@b8-medscimonit-22-2340]--[@b10-medscimonit-22-2340]\]. In less than 1% of cases, HRS is of T cell origin \[[@b11-medscimonit-22-2340]\]. The pathogenesis of HL is only partially understood and includes genetic and environmental factors \[[@b2-medscimonit-22-2340] [@b6-medscimonit-22-2340]\]. Genetic lesions frequently involve members of the NFκB family and the Jak-Stat signaling pathway, pointing to their central role in the pathogenesis, but multiple signaling pathways exist and cooperate \[[@b3-medscimonit-22-2340],[@b4-medscimonit-22-2340]\]. Epstein-Barr virus (EBV) can be found in HRS in 40% of cHL in the Western world, and in 90--100% in developing countries, such as those in Africa and Latin America \[[@b5-medscimonit-22-2340]--[@b7-medscimonit-22-2340]\]. EBV-positive HL is more frequent in children, older adult males, and mixed cellularity subtype of cHL \[[@b6-medscimonit-22-2340]\]. Older individuals with EBV-positive HL have a worse prognosis compared to young adults with EBV-positive HL, who have longer disease-free survival (DFS) \[[@b6-medscimonit-22-2340],[@b12-medscimonit-22-2340]\]. In cHL, EBV expresses a limited set of latent viral genes: EBNA1, LMP1, LMP2A, EBER1, and EBER2 \[[@b13-medscimonit-22-2340]\]. The tumor microenvironment of cHL is composed of mixtures of lymphocytes, plasma cells, macrophages, eosinophils, and mastocytes \[[@b14-medscimonit-22-2340],[@b15-medscimonit-22-2340]\]. In the last decade, regulatory T cells (Treg) have been studied extensively in non-tumor and tumor pathology \[[@b16-medscimonit-22-2340]\]. Treg are developmentally and functionally distinct T cell subpopulations engaged in sustaining immunological self-tolerance and homeostasis \[[@b17-medscimonit-22-2340]\]. FOXP3, a forkhead winged-helix transcriptional factor, is considered as a lineage-specific marker for Treg necessary for their development and function, as the majority of Treg are FOXP3-positive \[[@b17-medscimonit-22-2340]--[@b22-medscimonit-22-2340]\]. In the tumor microenvironment, Treg exert their suppressive activity on effector T cells (Teff), fostering immune privilege for tumor cells \[[@b21-medscimonit-22-2340]--[@b25-medscimonit-22-2340]\]. Unlike the majority of solid tumors, in which high numbers of Treg are connected to poor outcome, in HL it is associated with favorable outcome \[[@b24-medscimonit-22-2340],[@b26-medscimonit-22-2340]--[@b28-medscimonit-22-2340]\]. Treg have been studied in HL in the context of EBV status, but without identifying Treg subsets \[[@b26-medscimonit-22-2340],[@b29-medscimonit-22-2340]--[@b31-medscimonit-22-2340]\]. The aim of our study was to analyze T cell composition in cHL with special emphasis on Treg and Treg subtypes in regard to EBV status, cHL subtype, and patient age.

Material and Methods
====================

This retrospective case-control study included patients diagnosed with cHL in a 12-year period (1997--2009) at the Department of Pathology, Forensic Medicine, and Cytology, Clinical Hospital Center Split, Croatia. Paraffin blocks of tumor tissue were retrieved from the Department's archive, and were reviewed and classified according to WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2008. All samples were taken prior the initiation of treatment (cytostatic or irradiation). Inclusion criteria were: sufficient amount of tumor tissue in paraffin block, as well as all the necessary patient data (age, sex, and HL subtype). All cases that did not fulfill the criteria were excluded. A total of 102 cases were included. Approval for the study was obtained from the Hospital Ethics Committee (code 2181-147-08-01/01-M.J.).

Paraffin-embedded tissue samples were cut into slices 3-μm-thick, deparaffinized, and dehydrated. For antigen retrieval, slides were incubated for 20 min in TRIS/EDTA buffer, pH 9 (Dako, Denmark). Endogenous peroxidase activity was blocked by adding 200 μl of 3% H~2~O~2~. After rinsing in phosphate-buffered saline (PBD), monoclonal antibodies were applied. EBV status was assessed using LMP-1 mouse monoclonal antibody (clone CS1-4, Dako, Denmark), and results were interpreted based on brown membranous staining in HRS cells. For double-immunohistochemistry staining, the EnVisionTM G/2 Double stain System and Rabbit/Mouse DAB+Permanent Red, Dako, Denmark) were used according to the manufacturer's instructions.

Monoclonal mouse antibody against FOXP3 (236A/E7, Santa Cruz Biotechnology, Inc.) was applied first (1:50), incubated overnight in a humidity-controlled chamber, and then the staining process was finished in a Dako Autostainer using the standard manufacturer's protocol. Consecutively, monoclonal antibody CD4 (clone 4 B12, Novocastra, UK, 1:100) or monoclonal antibody CD8 (clone DK35, Dako, Denmark 1:100) was applied, incubated for 1 h, and the procedure was finished using the standard manufacturer's protocol. DAB was used as a chromogen to identify FOXP3 and Permanent Red was used to identify CD4 or CD8. Positive results were identified as brown nuclear staining of FOXP3 and red membranous staining for CD4 or CD8 ([Figure 1](#f1-medscimonit-22-2340){ref-type="fig"}). Slides were analyzed with an Olympus BX41 microscope at 1000×, photographed with an Olympus digital camera, and analyzed with the Analysis program (Soft Imaging System analysis program). The number of FOXP3 cells, CD4, CD8, and dual-positive FOXP3+CD4+ and FOXP3+CD8+ cells were counted in 10 random fields and expressed as total cell number.

For statistical analysis, the Mann-Whitney test, log-rank test, and χ^2^ test were used. Results were considered significant at *P*\<0.05.

Results
=======

Of the 102 patients, 53 (52%) were males and 49 (48%) were females. Median age was 36 years (range, 5--87); 24.5% patients were younger than 26.5 years, 26.5% were 26.5--36 years, 25.5% were 36.1--54 years, and 23.5% were \>54 years old. According to the expression of LMP1 in malignant cells, EBV status was negative in 72 (71%) patients and was positive in 30 (29%) patients. Subtypes were: 62% nodular sclerosis (NS), 24.5% mixed cellularity (MC), and 13.5% lymphocyte-rich (LR) and lymphocyte-depleted (LD) subtypes together. The absolute numbers of FOXP3+, CD4+, CD8+, FOXP3+CD4+, and FOXP3+CD8+ cells in the microenvironment, counted in 10 high-power magnification fields, are shown in [Table 1](#t1-medscimonit-22-2340){ref-type="table"}.

There was a statistically significant correlation between EBV status and patient age (χ^2^=43.9; *P*\<0.001). EBV-positive HL was 13 times more frequent in patients older than 54 years than in younger patients (p\<0.001). Most of the EBV-positive HL were of MC subtype (*P*=0.001). EBV-positive HL also had higher numbers of FOXP3+ (χ^2^=6.8*; P*=0.009) and CD8+ (χ^2^=4.27; *P*=0.029) cells. Twice as many FOXP3+CD4+ cells were found in EBV-positive compared with EBV-negative cases (χ^2^=6.8 *P*=0.009). EBV-negative cases contained more CD4+ cells (χ^2^=7.31; *P*=0.007) ([Table 2](#t2-medscimonit-22-2340){ref-type="table"}). Correlation of cHL subtypes showed that NS and MC contained more FOXP3+ (p=0.014) and FOXP3+CD4+ cells compared to LD and LR subtypes (χ^2^=21.890, p=0.004) (data not shown).

When correlating age groups with total number of all T cell types, we found that patients younger than 26.5 years had higher numbers of CD4+ cells compared to patients aged 26.5--36 years (χ^2^=21.890, *P*=0.009). Distribution of FOXP3+CD8+ cells was so variable that no statistical differences were found. The findings are summarized in [Table 3](#t3-medscimonit-22-2340){ref-type="table"}.

Discussion
==========

Results of our study showed that EBV-positive cHL contains generally higher number of FOXP3+Treg than EBV-negative cHL, and FOXP3+CD4+ Treg are the dominant Treg population. In EBV-negative cHL, higher numbers of non-regulatory CD4+ cells were found. We observed that the number of CD4+ cells decreased with age at some point after age 26 years. Distribution of FOXP3+CD8+ Treg was so variable that no clear associations were found. We found that 29% of cHL were EBV-positive, and most of these patients were older than 54 years and had MC subtype, which is in concordance with previous findings \[[@b1-medscimonit-22-2340]\]. Our results show that our study population fit the "Western" population pattern, with approximately 30% EBV-positive cHL in immunocompetent patients. Previous studies have shown that the cHL microenvironment is enriched in Treg, and their high number could explain immune evasion of HRS \[[@b29-medscimonit-22-2340],[@b30-medscimonit-22-2340]\]. HRS cells express ligands CCL17, CCL22, and Galectin 1, which selectively attract CCR4 Treg to the cHL microenvironment \[[@b15-medscimonit-22-2340],[@b32-medscimonit-22-2340]\]. HRS cells also express IL21, which upregulates CC chemokine macrophage-inflammatory protein-3α and attracts FOXP3+ Treg \[[@b33-medscimonit-22-2340]\]. Baumforth et al. found that in EBV-positive cHL, EBNA1 upregulates expression of CCL20 in HRS cells, resulting in the increased migration of FOXP3+ cells to the microenvironment \[[@b31-medscimonit-22-2340]\]. Although most authors agree that the cHL microenvironment is enriched in Treg, no clear evidence of greater bias toward higher number of Treg in EBV-positive cHL has been found \[[@b26-medscimonit-22-2340],[@b27-medscimonit-22-2340],[@b29-medscimonit-22-2340]--[@b31-medscimonit-22-2340]\]. Results from a study by Assis et al. were somewhat similar to ours. They performed qualitative and quantitative analysis of Treg in 130 cases of cHL in a Brazilian population and found that the presence of EBV correlates with increased number of CD4+CD25+FOXP3+ Treg, but there was no association between Treg and clinical characteristics \[[@b34-medscimonit-22-2340]\]. Unlike Baumforth et al., we found higher numbers of FOXP3+Treg and FOXP3+CD4+ cells in EBV-positive cHL \[[@b31-medscimonit-22-2340]\]. This may be because our study was performed with a larger number of patients. CD4+ lymphocytes are the dominant T cells in the cHL microenvironment \[[@b35-medscimonit-22-2340]\]. We found increased numbers of CD4+ cells in EBV-negative cHL cases. According to Baumforth et al., this could partially be explained by the absence of EBNA1 effect on migration of Treg \[[@b31-medscimonit-22-2340]\]. Morales et al. recently reported that EBV is responsible for enrichment of the HL microenvironment with regulatory Type 1 cells (Tr1) by increasing gene expression of Tr1-related markers and associated immunosuppressive cytokines, such as interleukin 10. This observation suggests that differences in EBV-positive and EBV-negative cHL Treg pools could be even bigger and include new molecules and regulatory mechanisms \[[@b36-medscimonit-22-2340]\]. Kyatsu et al. analyzed the T cell microenvironment in HIV-associated HL, which is always an EBV-positive neoplasm. They found that the HIV-associated HL microenvironment contained significantly lower proportions of FOXP3+ Treg and higher proportions of CD8+ cells, compared to control HIV-negative HL patients. Also, in the control group, EBV-positive HL was associated with more FOXP3+ cells and CD8+ cells than in EBV-negative HL, which is in agreement with our results \[[@b37-medscimonit-22-2340]\]. Although the majority of CD8 cells are directed toward EBV antigens expressing latency III program, LMP1 and LMP2 can also act as immunogens for CD8+ cells \[[@b38-medscimonit-22-2340]\]. Kyatsu et al. reported that the abundant CD8+ cells present in HIV-associated HL probably are not LMP-specific cytotoxic cells, but rather immature anergic cells \[[@b37-medscimonit-22-2340]\]. Cosmi et al. considered that increased number of CD8+ in EBV-positive HL in immunocompetent patients do not necessarily reflect antiviral immune response, but perhaps are a part of the total regulatory pool \[[@b39-medscimonit-22-2340]\]. CD8 regulatory T cells share functional characteristics with CD4+ Treg; they are anergic (do not produce perforin or granzyme) and immunosuppressive (their effectiveness in viral-induced tumors is questionable) \[[@b39-medscimonit-22-2340], [@b40-medscimonit-22-2340]\]. We showed that the number of FOXP3+CD8^+^ cells in the cHL microenvironment is variable and without statistically significant differences. CD8+ Treg can be FOXP3-, which could mean that the number of CD8+Treg cells was underestimated by FOXP3 expression alone, and other markers are necessary to assess the CD8 Treg "pool" \[[@b20-medscimonit-22-2340]\]. We found a decreased number of CD4 cells in the cHL microenvironment in individuals older than 26 years, which may reflect a normal process of immune senescence due to decreased thymic output of Teff and Treg cells \[[@b40-medscimonit-22-2340]\]. We did not find a difference in Treg according to age, which agrees with the results of Dejaco and Fessler, who considered that the number of Treg cells remains the same, but their function is changed \[[@b41-medscimonit-22-2340],[@b42-medscimonit-22-2340]\]. In contrast, Raynor reported that aging is associated with increased number of Treg cells, with consequent increased incidence of tumors and autoimmune diseases \[[@b43-medscimonit-22-2340]\]. Our previous study showed that younger individuals (\<35 years old) with EBV-positive cHL have longer disease-free survival \[[@b12-medscimonit-22-2340]\]. We expected to find that younger individuals with EBV-positive cHL would have higher numbers of FOXP3+ Treg, but we did not find this correlation. The cHL Treg pool is probably highly heterogeneous, comprising FOXP3+ and FOXP3-- suppressor cells among CD4 and CD8, as well as other cell types. Other possible mechanisms maybe exist that ensure better outcome in young individuals with EBV-positive cHL.

Conclusions
===========

Epstein-Barr viral status has an impact on the composition of the T cell population in cHL. In cHL with positive EBV status, the microenvironment is more enriched with FOXP3+ Treg, mainly FOXP3+CD4 cells. Aging has an impact on CD4+ numbers, but does not affect the number of Treg cells in cHL.
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![Double immunostaining for FOXP3 and CD4 and CD8 expression in classical Hodgkin lymphoma. FOXP3 expression is shown as nuclear brown staining and CD4 or CD8 expression as membranous red staining. Double-positive cells show combined nuclear brown and membranous red staining. (**A**) Numerous double-positive FOXP3/CD4 cells and single-positive CD4 cells. (**B**) Rare double-positive FOXP3/CD4 cells and numerous single-positive CD4 cells. (**C**) Some double-positive FOXP3/CD8 cells with single-positive CD8 cells. (**D**) No double-positive FOXP3/CD8 cell and some single-positive CD8 cells.](medscimonit-22-2340-g001){#f1-medscimonit-22-2340}

###### 

Distribution of T cell phenotypes in microenvironment of classic Hodgkin lymphoma on 10 high power magnification fields.

  Phenotype    Median (min-max) N
  ------------ --------------------
  FOXP3+       536 (17--2368)
  CD4+         2920 (708--5318)
  FOXP3+CD4+   414 (16--2355)
  CD8+         656 (33--2899)
  FOXP3+CD8+   4 (0--431)

###### 

Correlation of EBV status with clinical and histological parameters in 102 cases of cHL.

  ------------------------------------------------------------------------------------
  Parameter             LMP1−\     LMP1+\     χ^2^    OR (95%CI)             *P*
                        N=72 (%)   N=30 (%)                                  
  ----------- --------- ---------- ---------- ------- ---------------------- ---------
  Sex         M         37 (51)    16 (53)    0.032   0.925 (0.394--2.17)    0.585

  F           35 (49)   14 (47)                                              

  Age         \<54      68 (94)    10 (33)    43.90   3.4 (9.6--12.0)        \<0.001

  \>54.1      4 (6)     20 (67)                                              

  Subtype     NS        50 (70)    13 (43)    11.28   1.465 (0.829--2.59)    0.189

  MC          11 (15)   14 (47)                                              

  LP and LD   11 (15)   3 (10)                                               

  FOXP3+      \<536.5   42 (58)    9 (30)     6.8     3.27 (1.3--8.1)        0.011

  \>536.51    30 (41)   21 (70)                                              

  CD4+        \<3464    49 (68)    28 (93)    7.31    0.674 (0.451--1.006)   0.053

  \>3464.1    23 (32)   2 (7)                                                

  CD8+        \<656.5   41 (57)    10 (33)    4.72    2.64 (1.09--6.45)      0.032

  \>656.51    31 (43)   20 (67)                                              

  FOX+CD4+    \<414.5   42 (58)    9 (30)     6.8     3.27 (1.31--8.1)       0.011

  \>414.51    30 (42)   21 (70)                                              
  ------------------------------------------------------------------------------------

###### 

Correlation of patient's age with number of T cells.

  T cells parameter   N          Age (years)   χ^2^      *P*                         
  ------------------- ---------- ------------- --------- --------- -------- -------- -------
  FOXP3+              \<227.75   7 (28)        3 (11)    10 (39)   5 (21)   9.650    0.380
  227.75--536,5       8 (32)     6 (22)        7 (27)    5 (21)                      
  536.55--902         5 (20)     8 (30)        6 (23)    7 (29)                      
  \>902.1             5 (20)     10 (37)       3 (11)    7 (29)                      
  CD8+                \<293      8 (32)        10 (37)   4 (15)    3 (12)   11.148   0.266
  293.1--656.5        6 (24)     7 (26)        8 (31)    5 (21)                      
  656.5--1056.5       3 (12)     5 (18.5)      8 (31)    10 (42)                     
  \>1056.5            8 (32)     5 (18.5)      6 (23)    6 (25)                      
  FOX+CD8+            0                                                              
  0.0001--4                                                                          
  4001--30.75         1 (4)                    1 (4)     1 (4)     1.117    0.773    
  \>30.75             24 (96)    27 (100)      25 (96)   23 (96)                     
  CD4+                \<2363     6 (24)        7 (26)    4 (15)    8 (33)   21.890   0.009
  2363.1--2920.5                 13 (48)       8 (31)    5 (21)                      
  2920.5--3464        9 (36)     4 (15)        6 (23)    7 (29)                      
  \>3464.1            10 (40)    3 (11)        8 (31)    4 (17)                      
  FOX+CD4+            \<188.75   6 (24)        4 (15)    9 (35)    6 (25)   9.336    0.407
  188.75--414.5       9 (36)     5 (18)        8 (31)    4 (17)                      
  414.5--811.75       5 (20)     8 (30)        6 (23)    7 (29)                      
  \>811.75            5 (20)     10 (37)       3 (11)    7 (29)                      
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